Wells Fargo analyst Larry Biegelsen recently initiated coverage of GE Healthcare (GEHC) stock and assigned it a Buy rating with a price target of $90. One of the main factors contributing to this positive outlook is the sales generated from the company's Alzheimer's treatment.

Approval for Alzheimer's Disease Drug

On July 6, the FDA granted Leqembi, a drug developed by Japanese pharmaceutical companies Eisai and Biogen, traditional approval for the treatment of Alzheimer's disease. As part of the treatment process, patients are required to undergo four MRI scans before and during the course of treatment, in addition to PET scans and doses of an imaging agent.

Growth Potential

With its expertise in manufacturing and servicing imaging equipment, GE is well-positioned to benefit from the increased demand for Leqembi. Biegelsen estimates that the company could generate an additional $500 million in sales from Leqembi-related business by 2027, surpassing the overall market growth rate. As a result, GE is expected to experience a "double-digit" earnings growth rate in the coming years.

Analyst Consensus

The positive outlook for GE Healthcare Technologies is echoed by analysts on Wall Street. Sales projections for 2023 stand at $19.5 billion, increasing to $24.9 billion by 2027. Furthermore, earnings per share are projected to grow at an average annual rate of 15% over the span of this period.

GE HealthCare Receives Buy Rating from Analysts

GE HealthCare's stock is showing positive movement in premarket trading, with a 1.4% increase to $71.50 per share. In comparison, futures for the S&P 500 and Dow Jones Industrial Average remain flat.

Analysts have recently assigned a Buy rating to GE HealthCare, with 58% of them recommending the stock. This surpasses the average Buy-rating ratio of approximately 55% for S&P 500 stocks. Currently, twelve analysts cover GE HealthCare, according to FactSet.

Following the spin-off from General Electric (GE) in early 2023, it took some time for analyst coverage to gain momentum. In contrast, peers such as Siemens Healthineers (SHL.Germany) and Abbott Laboratories (ABT) already have 20 and 25 analysts covering their stocks, respectively.

The average analyst price target for GE HealthCare stands at around $90 per share, aligning with Biegelsen's perspective.

If GE HealthCare's stock reaches $90 per share, it would trade at approximately 21 times the estimated earnings for 2024. On the other hand, Siemens Healthineers stock has a price-to-earnings ratio of about 19 based on current trading levels, rather than analysts' target prices. The average analyst target price for Siemens Health stock is about 63 euros, leading to a price-to-earnings ratio of around 25 for the estimated earnings of 2024.

Grand City Properties Raises Guidance for 2023

Chinese Developer Country Garden Faces Downgrade

Leave A Reply

Your email address will not be published. Required fields are marked *

Related posts

Marvell Technology Inc. Emerges as Top Specialty Chip Pick for 2024
News

Marvell Technology Inc. Emerges as Top Specialty Chip Pick for 2024

Citi analyst predicts Marvell Technology Inc. to outperform Nvidia Corp. in the specialty chip market in 2024, citing po...

Thai Shares Show Modest Gain
News

Thai Shares Show Modest Gain

The Thai stock market showed a modest gain, with top gainers and losers in the technology sector. Updates on other South...

Supreme Court Blocks Lower-Court Order on Social Media Posts
News

Supreme Court Blocks Lower-Court Order on Social Media Posts

The Supreme Court has blocked a lower-court order aimed at restricting social media posts on COVID-19 and election secur...

IMI Reports 15% Rise in H1 Pretax Profit
News

IMI Reports 15% Rise in H1 Pretax Profit

IMI reports a 15% rise in pretax profit for the first half of the year and backs its full-year projections. Revenue and...